Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

An exploratory investigation of brain-selective estrogen treatment in males using a mouse model of Alzheimer's disease.

Tschiffely AE, Schuh RA, Prokai-Tatrai K, Ottinger MA, Prokai L.

Horm Behav. 2018 Feb;98:16-21. doi: 10.1016/j.yhbeh.2017.11.015. Epub 2017 Dec 22.

2.

A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease.

Tschiffely AE, Schuh RA, Prokai-Tatrai K, Prokai L, Ottinger MA.

Horm Behav. 2016 Jul;83:39-44. doi: 10.1016/j.yhbeh.2016.05.009. Epub 2016 May 19.

3.

Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease.

Amtul Z, Wang L, Westaway D, Rozmahel RF.

Neuroscience. 2010 Aug 25;169(2):781-6. doi: 10.1016/j.neuroscience.2010.05.031. Epub 2010 May 21.

PMID:
20493928
4.

Estrogen treatment improves spatial learning in APP + PS1 mice but does not affect beta amyloid accumulation and plaque formation.

Heikkinen T, Kalesnykas G, Rissanen A, Tapiola T, Iivonen S, Wang J, Chaudhuri J, Tanila H, Miettinen R, Puoliväli J.

Exp Neurol. 2004 May;187(1):105-17.

PMID:
15081593
5.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14.

PMID:
21513747
6.

Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease.

Xiong H, Callaghan D, Wodzinska J, Xu J, Premyslova M, Liu QY, Connelly J, Zhang W.

Neurosci Bull. 2011 Aug;27(4):221-32. doi: 10.1007/s12264-011-1015-7.

7.

The prodrug DHED selectively delivers 17β-estradiol to the brain for treating estrogen-responsive disorders.

Prokai L, Nguyen V, Szarka S, Garg P, Sabnis G, Bimonte-Nelson HA, McLaughlin KJ, Talboom JS, Conrad CD, Shughrue PJ, Gould TD, Brodie A, Merchenthaler I, Koulen P, Prokai-Tatrai K.

Sci Transl Med. 2015 Jul 22;7(297):297ra113. doi: 10.1126/scitranslmed.aab1290.

8.

A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.

Jeon S, Bose S, Hur J, Jun K, Kim YK, Cho KS, Koo BS.

J Ethnopharmacol. 2011 Sep 1;137(1):783-9. doi: 10.1016/j.jep.2011.06.046. Epub 2011 Jul 5.

PMID:
21762767
9.

Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease.

Edwards SR, Hamlin AS, Marks N, Coulson EJ, Smith MT.

Clin Exp Pharmacol Physiol. 2014 Oct;41(10):798-806. doi: 10.1111/1440-1681.12277.

PMID:
25115283
10.

The Effects of Cardiotrophin-1 on Early Synaptic Mitochondrial Dysfunction and Synaptic Pathology in APPswe/PS1dE9 Mice.

Wang D, Liu X, Liu Y, Li S, Wang C.

J Alzheimers Dis. 2017;59(4):1255-1267. doi: 10.3233/JAD-170100.

PMID:
28731433
11.

Brain endogenous estrogen levels determine responses to estrogen replacement therapy via regulation of BACE1 and NEP in female Alzheimer's transgenic mice.

Li R, He P, Cui J, Staufenbiel M, Harada N, Shen Y.

Mol Neurobiol. 2013 Jun;47(3):857-67. doi: 10.1007/s12035-012-8377-3. Epub 2012 Nov 20.

12.

The impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer's disease.

Rantamäki T, Kemppainen S, Autio H, Stavén S, Koivisto H, Kojima M, Antila H, Miettinen PO, Kärkkäinen E, Karpova N, Vesa L, Lindemann L, Hoener MC, Tanila H, Castrén E.

PLoS One. 2013 Jul 3;8(7):e68722. doi: 10.1371/journal.pone.0068722. Print 2013.

13.

Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer's-like disease in mice.

von Linstow CU, Waider J, Grebing M, Metaxas A, Lesch KP, Finsen B.

Alzheimers Res Ther. 2017 Sep 12;9(1):74. doi: 10.1186/s13195-017-0298-y.

14.

Estrogen therapy fails to alter amyloid deposition in the PDAPP model of Alzheimer's disease.

Green PS, Bales K, Paul S, Bu G.

Endocrinology. 2005 Jun;146(6):2774-81. Epub 2005 Feb 24.

PMID:
15731362
15.

Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.

Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR.

Neurobiol Dis. 2005 Apr;18(3):602-17.

PMID:
15755686
16.

A detailed analysis of the early context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease.

Bonardi C, de Pulford F, Jennings D, Pardon MC.

Behav Brain Res. 2011 Sep 12;222(1):89-97. doi: 10.1016/j.bbr.2011.03.041. Epub 2011 Mar 31.

PMID:
21440575
17.

Cardiotrophin-1 (CTF1) ameliorates glucose-uptake defects and improves memory and learning deficits in a transgenic mouse model of Alzheimer's disease.

Wang D, Li X, Gao K, Lu D, Zhang X, Ma C, Ye F, Zhang L.

Pharmacol Biochem Behav. 2013 Jun;107:48-57. doi: 10.1016/j.pbb.2013.03.003. Epub 2013 Mar 26.

PMID:
23541490
18.
19.

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.

Hansen HH, Fabricius K, Barkholt P, Kongsbak-Wismann P, Schlumberger C, Jelsing J, Terwel D, Termont A, Pyke C, Knudsen LB, Vrang N.

PLoS One. 2016 Jul 15;11(7):e0158205. doi: 10.1371/journal.pone.0158205. eCollection 2016.

20.

17Alpha-estradiol and 17beta-estradiol treatments are effective in lowering cerebral amyloid-beta levels in AbetaPPSWE transgenic mice.

Levin-Allerhand JA, Lominska CE, Wang J, Smith JD.

J Alzheimers Dis. 2002 Dec;4(6):449-57.

PMID:
12515896

Supplemental Content

Support Center